Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lung Neoplasms 8Carcinoma, Non-Small-Cell Lung 6Breast Neoplasms 4Prostatic Neoplasms 3Wilms Tumor 2Small Cell Lung Carcinoma 2Sarcoma, Ewing 2Rectal Neoplasms 2Pulmonary Disease, Chronic Obstructive 2Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2Head and Neck Neoplasms 2Glioma 2Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Tuberculosis 1Thoracic Cancer 1Shwachman-Diamond Syndrome 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Recurrence 1Precancerous Conditions 1Pneumonia 1Pathologic Complete Response 1Pancreatic Intraductal Neoplasms 1Osteosarcoma 1Osteoporosis 1

Interventions

Rituximab 168Cyclophosphamide 142Peripheral Blood Stem Cell Transplantation 84fludarabine phosphate 68Filgrastim 64Etoposide 63Radiotherapy 55Vincristine 47Prednisone 45Mycophenolic Acid 44Melphalan 40Whole-Body Irradiation 39Cyclosporine 39Busulfan 39Tacrolimus 36Doxorubicin 34Cytarabine 33Lenalidomide 29Carmustine 28Antilymphocyte Serum 28Methotrexate 27Methylprednisolone 26Bortezomib 26Bendamustine Hydrochloride 26sargramostim 21ibritumomab tiuxetan 20obinutuzumab 19ibrutinib 18fludarabine 18Dexamethasone 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphoma, Follicular × X-Rays × Clear all
NCT00438880 2016-02-04

Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma

Mayo Clinic

Phase 1/2 Completed
38 enrolled 8 charts
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡